Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07518329
PHASE1

Study of ALA-101 in Patients With CD19 Positive Non-Hodgkin Lymphoma and Leukemia.

Sponsor: Arovella Therapeutics Ltd

View on ClinicalTrials.gov

Summary

Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101

Official title: A Phase 1 Open-Label Dose-Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ALA-101, Allogeneic, Off-the-shelf, CD19-directed CAR-iNKT Cells in Patients With CD19+ Non-Hodgkin Lymphoma and Leukemia

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

46

Start Date

2026-08-20

Completion Date

2030-08-30

Last Updated

2026-08-06

Healthy Volunteers

No

Interventions

DRUG

ALA-101

Single IV infusion of ALA-101 post chemotherapy conditioning with Fludarabine and Cyclophosphamide

Locations (5)

St. Vincent's Hospital

Sydney, New South Wales, Australia

Mater Misericordiae Ltd (MML)

Brisbane, Queensland, Australia

Royal Adelaide Hospital

Adelaide, South Australia, Australia

The Alfred Hospital

Melbourne, Victoria, Australia

Epworth HealthCare

Richmond, Victoria, Australia